



Pharmaero ApS

CVR no. 32 82 79 42

Dalslandsgade 11, 2300 Copenhagen S

Annual report for 2017

Adopted at the annual general meeting on 4
April 2018

A handwritten signature in blue ink, appearing to be "Mats Persson", written over a horizontal line.

Mats Persson
chairman

Contents

	Page
Statements	
Statement by management on the annual report	1
Independent auditor's report	2
Management's review	
Company details	5
Management's review	6
Financial statements	
Income statement 1 January - 31 December	7
Balance sheet 31 December	8
Statement of changes in equity	10
Notes to the annual report	11
Accounting policies	13

Statement by management on the annual report

The supervisory and executive boards have today discussed and approved the annual report of Pharmaero ApS for the financial year 1 January - 31 December 2017.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2017 and of the results of the company's operations for the financial year 1 January - 31 December 2017.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and its financial position.

Management recommends that the annual report should be approved at the annual general meeting.

Copenhagen, 4 April 2018

Executive board



Pietro Crovetto

Supervisory board



Mats Persson
chairman



Aleksandar Danilovski



Carl-Ake Carlsson



Per Martin Linse

Independent auditor's report

To the shareholders of Pharmaero ApS

Opinion

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2017, and of the results of the Company's operations for the financial year 1 January - 31 December 2017 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Pharmaero ApS for the financial year 1 January - 31 December 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies ("financial statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on management's review

Management is responsible for management's review.

Our opinion on the financial statements does not cover management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Independent auditor's report

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

Independent auditor's report

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Copenhagen, 4 April 2018

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
CVR no. 33 77 12 31



Kim Fuchsøl
State Authorised Public Accountant
MNE no. 9291



Conrad Mattrup Lundsgaard
State Authorised Public Accountant
MNE no. 34529

Company details

The company	Pharmaero ApS Dalslandsgade 11 2300 Copenhagen S
	Telephone: +4532645500
	CVR no.: 32 82 79 42
	Reporting period: 1 January - 31 December 2017
	Domicile: Copenhagen S
Supervisory board	Mats Persson, chairman Carl-Åke Carlsson Per Martin Linse Aleksandar Danilovski
Executive board	Pietro Crovetto
Auditors	PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Strandvejen 44 DK-2900 Hellerup

Management's review

Business activities

The activities of Pharmaero ApS are development and sales of pharmaceutical products for human use.

Business review

The Company's income statement for the year ended 31 December shows a loss of TDKK 1.450, and the balance sheet at 31 December 2017 shows equity of TDKK 100.375.

Outlook

The Company expects an activity level at the same level as in 2017.

Significant events occurring after end of reporting period

No events have occurred after the balance sheet date which could significantly affect the company's financial position.

Income statement 1 January - 31 December

	Note	2017 TDKK	2016 TDKK
Revenue		<u>0</u>	<u>1</u>
Gross profit		0	1
Administrative costs		-1.255	-668
Research cost		<u>-527</u>	<u>0</u>
Operating profit/loss		-1.782	-667
Financial costs		<u>-62</u>	<u>-15</u>
Profit/loss before tax		-1.844	-682
Tax on profit/loss for the year	1	<u>394</u>	<u>22</u>
Net profit/loss for the year		<u>-1.450</u>	<u>-660</u>
Proposed distribution of profit			
Transferred to other statutory reserves		23.915	20.730
Retained earnings		<u>-25.365</u>	<u>-21.390</u>
		<u>-1.450</u>	<u>-660</u>

Balance sheet 31 December

	Note	2017 TDKK	2016 TDKK
Assets			
Development projects in progress		120.819	90.159
Intangible assets	2	120.819	90.159
Fixed assets total		120.819	90.159
Other receivables		1.793	3.322
Corporation tax		5.500	5.500
Prepayments		25	0
Receivables		7.318	8.822
Cash at bank and in hand		4.059	9.301
Current assets total		11.377	18.123
Assets total		132.196	108.282

Balance sheet 31 December

	Note	2017 TDKK	2016 TDKK
Liabilities and equity			
Share capital		8.180	7.060
Reserve for development expenditure		44.645	20.730
Retained earnings		47.550	60.035
Equity	3	100.375	87.825
Provision for deferred tax	4	16.998	11.892
Provisions total		16.998	11.892
Trade payables		4.286	8.187
Other payables		10.537	378
Short-term debt		14.823	8.565
Debt total		14.823	8.565
Liabilities and equity total		132.196	108.282
Staff	5		
Subsequent events	6		
Contingent assets, liabilities and other financial obligations	7		
Related parties and ownership	8		

Statement of changes in equity

	Share capital	Reserve for development expenditure	Retained earnings	Total
Equity at 1 January	7.060	20.730	60.035	87.825
Cash capital increase	1.120	0	12.880	14.000
Net profit/loss for the year	0	23.915	-25.365	-1.450
Equity at 31 December	8.180	44.645	47.550	100.375

	Share capital	Reserve for development expenditure	Retained earnings	Total
Equity 1. januar 2016	5.212	0	60.173	65.385
Cash capital increase	1.848	0	21.252	23.100
Net profit/loss for the year	0	20.730	-21.390	-660
Equity 31. december 2016	7.060	20.730	60.035	87.825

Notes

	2017	2016
	TDKK	TDKK
1 Tax on profit/loss for the year		
Current tax for the year	-5.500	-5.500
Deferred tax for the year	5.106	5.350
Adjustment of tax concerning previous years	0	128
	<u>-394</u>	<u>-22</u>

2 Intangible assets

	Development projects in progress
Cost at 1 January	90.159
Additions for the year	<u>30.660</u>
Cost at 31 December	<u>120.819</u>
Impairment losses and amortisation at 31 December	<u>0</u>
Carrying amount at 31 December	<u>120.819</u>

Development projects are related to development of existing and new versions of existing pharmaceutical products. Pharmaero capitalizes development cost when the projects can demonstrate a future economic benefit. The projects are progressing as planned using the resources management have allocated to development projects. It is expected that the products will be sold at the current market.

3 Equity

The share capital has developed as follows:

	2017	2016	2015	2014	2013
	TDKK	TDKK	TDKK	TDKK	TDKK
Share capital at 1 January	7.060	5.212	4.414	3.966	2.654
Additions for the year	<u>1.120</u>	<u>1.848</u>	<u>798</u>	<u>448</u>	<u>1.312</u>
Share capital	<u>8.180</u>	<u>7.060</u>	<u>5.212</u>	<u>4.414</u>	<u>3.966</u>

Notes

	2017	2016
	TDKK	TDKK
4 Provision for deferred tax		
Provision for deferred tax at 1 January	11.892	6.542
Provision in year	5.106	5.350
Provision for deferred tax at 31 December	16.998	11.892
Intangible assets	26.580	19.835
Tax loss carry-forward	-9.582	-7.943
	16.998	11.892

	2017	2016
	TDKK	TDKK
5 Staff		
Average number of employees	1	0

According to the Danish Financial Statements Act section 98B (3), remuneration to the Executive Board has not been disclosed.

6 Subsequent events

No events have occurred after the balance sheet date which may materially affect the Company's financial position.

7 Contingent assets, liabilities and other financial obligations

The Company has no contingencies or economical liabilities other than included in the Annual Report and notes.

8 Related parties and ownership

Ownership

According to the Company's register of shareholders, the following shareholders hold a minimum of 5% of the voting rights or a minimum of 5% of the share capital:

Xellia Pharmaceuticals ApS, Denmark, 50 %
Scandinavian Heath Limited, Taiwan, 50%

Accounting policies

The Annual Report of Pharmaero ApS for 2017 has been prepared in accordance with the provisions applying to reporting class B enterprises under the Danish Financial Statements Act with additions from reporting class big C about development projects.

The accounting policies applied are consistent with those of last year.

The annual report for 2017 is presented in TDKK

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any instalments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Income statement

Revenue

Revenue is measured at the fair value of the agreed consideration, excluding VAT and other indirect taxes. Revenue is net of all types of discounts granted.

Administrative costs

Administrative costs comprise expenses for Management, administrative staff, office expenses, depreciation, etc.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year. Net financials include interest income and expenses, financial expenses relating to finance leases, realised and unrealised capital/exchange gains and losses on securities and foreign currency transactions, amortisation of mortgage loans and surcharges and allowances under the advance-payment-of-tax scheme, etc.

Accounting policies

Tax on profit/loss for the year

Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, including changes arising from changes in tax rates, is recognised in the income statement as regards the portion that relates to entries directly in equity.

Balance sheet

Intangible assets

Development projects

Development projects are capitalized when the development costs relate to new products or processes that are clearly defined and identifiable and the company can demonstrate a future economic benefit, the technical feasibility, sufficient resources, a future market and the intention of completing the intangible asset and ability to use or sell it as well as measure reliably the expenditure attributable to the development.

Development projects that do not fulfill these requirements are expensed.

Receivables

Receivables are measured at amortised cost.

Equity

Dividend

Proposed dividends are disclosed as a separate item under equity. Dividends are recognised as a liability at the date of declaration by the annual general meeting.

Capitalised development cost occurred from January 1, 2017 are reflected as an reserve in equity in accordance with the Danish Financial Act section 83.

Income tax and deferred tax

Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.

Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively.

Deferred tax assets, including the tax base of tax loss allowed for carry forward are measured at the value to which the asset is expected to be realised, either by elimination in tax on future income or by offsetting against deferred tax liabilities within the same legal tax entity. Any deferred net tax assets are measured at net realisable value.

Accounting policies

Liabilities

Financial liabilities are recognised on the raising of the loan at the proceeds received net of transaction costs incurred. On subsequent recognition, the financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest method. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan.

Other liabilities, which include trade receivables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign-exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.